Distinct CpG methylation profiles characterize different clinical groups of neuroblastic tumors

Barbara Banelli, Ilaria Gelvi, Angela Di Vinci, Paola Scaruffi, Ida Casciano, Giorgio Allemanni, Stefano Bonassi, Gian Paolo Tonini, Massimo Romani

Research output: Contribution to journalArticlepeer-review


The hypermethylation of CpG islands within gene promoter regions is an epigenetic phenomenon that is often, but not always, associated with the transcriptional silencing of downstream genes and contributes to carcinogenesis. We have determined the pattern of methylation of several genes involved in distinct biological pathways, including cell proliferation and apoptosis, in neuroblastoma and in the nonmalignant ganglioneuroma. The purpose of this work was to search for epigenetic signatures that could be associated with defined clinical and biological parameters and that, in prospective, could identify specific risk categories among the patients. We have analysed 31 malignant neuroblastoma with or without MYCN amplification and 13 benign ganglioneuroma and we have observed dramatic differences in the methylation pattern of five genes (CASP8, 14.3.3a, ΔN-p73, RASSF1A and DCR2) between these tumors indicating that this phenomenon is not tissue-specific and can be considered as cancer-dependent. Furthermore, the methylation pattern of 14.3.3σ, RASSF1A and of an intragenic segment of CASP8 was significantly different between MYCN amplified and single copy neuroblastoma suggesting a specific role of epigenetic alterations in aggressive neuroblastoma.

Original languageEnglish
Pages (from-to)5619-5628
Number of pages10
Issue number36
Publication statusPublished - Aug 25 2005


  • Ganglioneuroma
  • Methylation
  • Methylator phenotype
  • Neuroblastoma

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics


Dive into the research topics of 'Distinct CpG methylation profiles characterize different clinical groups of neuroblastic tumors'. Together they form a unique fingerprint.

Cite this